Results 11 to 20 of about 26,546 (243)
Treatment resistance in schizophrenia [PDF]
BMJ, 1996 Alternative drugs may offer clearer understanding of underlying mechanisms Since the 1950s, when chlorpromazine was introduced into psychiatric practice, antipsychotic drugs have been the cornerstone of the management of schizophrenia. They have three main functions: to treat the positive symptoms of acute schizophrenic episodes; to reduce ...
E C, Johnstone, R, Sandler
openaire +2 more sources
DTI study of corpus callosum in schizophrenia patients with different treatment response
Chinese Journal of Contemporary Neurology and Neurosurgery, 2021 Objective To compare the white matter fiber integrity of corpus callosum in schizophrenia patients with different treatment response with normal controls.
SHI Xiao⁃meng +4 more
doaj +1 more source
Cortico-cognition coupling in treatment resistant schizophrenia
NeuroImage: Clinical, 2022 Background: Brain structural alterations and cognitive dysfunction are independent predictors for poor clinical outcome in schizophrenia, and the associations between these domains remains unclear.
Warda T. Syeda +20 more
doaj +1 more source
Treatment of early resistant schizophrenia: a case report
European Psychiatry, 2023 Introduction Early-onset schizophrenia begins before the age of 18. Drug treatments are mainly based on antipsychotics, preferably atypical antipsychotics, which have fewer side effects compared to first generation antipsychotics.
S. Benhammou, M. Raissouni, H. Kisra
doaj +1 more source
European Psychiatry, 2022 Introduction Electroconvulsive therapy (ECT) is one of the oldest psychiatric treatments used to this day. It is particularly useful in cases of schizophrenia resistant to treatment with antipsychotics.
C. Adão +4 more
doaj +1 more source
Dissociative Model in Patients With Resistant Schizophrenia
Frontiers in Psychiatry, 2022 BackgroundSchizophrenia is a severe mental illness in which, despite the growing number of antipsychotics from 30 to 50% of patients remain resistant to treatment. Many resistance factors have been identified.
Georgi Panov
doaj +1 more source
Neurology International, 2021 The monoamine hypothesis of depression attributes the symptoms of major depressive disorders to imbalances of serotonin, noradrenaline, and dopamine in the limbic areas of the brain.
Amber N. Edinoff +7 more
doaj +1 more source
Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response
Scientific Reports, 2023 Glutamatergic dysfunction is associated with failure to respond to antipsychotic medication in individuals with schizophrenia. Our objective was to combine neurochemical and functional brain imaging methods to investigate glutamatergic dysfunction and ...
Elias D. Mouchlianitis +5 more
doaj +1 more source
Trends in Psychiatry and Psychotherapy, 2021 Objective To investigate epidemiological factors related to treatment-resistant schizophrenia (TRS) in Northeast Brazil, a region where data about mental health are still scarce.
Douglas de Sousa Soares +4 more
doaj +1 more source
Treatment-Resistant Schizophrenia
Focus, 2020 Although, gratifyingly, research on the treatment of schizophrenia has increasingly focused on first-episode and prodromal patient populations, it is still recognized that many patients with more chronic illnesses exhibit a suboptimal response to treatments.
openaire +3 more sources